BioPharma Credit PLC DIVIDEND DECLARATION (9760U)
29 November 2023 - 8:00AM
UK Regulatory
TIDMBPCR
RNS Number : 9760U
BioPharma Credit PLC
29 November 2023
29 November 2023
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
DIVIDEND DECLARATION
3.75 CENT PER SHARE DISTRIBUTION INCLUDES 2.0 CENT SPECIAL
DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, is pleased to declare an interim dividend in respect
of the financial period ended 30 September 2023 of $0.0375 per
ordinary share, payable on 5 January 2024 to ordinary shareholders
on the register as at 8 December 2023. The ex-dividend date will be
7 December 2023.
The Company has chosen to designate the entire amount of this
interim dividend as an interest distribution. Shareholders in
receipt of such a dividend will be treated for UK tax purposes as
though they have received a payment of interest. This will result
in a reduction in the corporation tax payable by the Company.
The $0.0375 dividend comprises an ordinary dividend of $0.0175
and a special dividend of $0.0200 The Company is currently paying
and continues to target a 7 cent annual dividend per ordinary
share.
The default payment for dividends is in US dollars. However,
shareholders can elect to have dividends paid in sterling (GBP) and
the option to elect a sterling dividend payment for this dividend
will be available to shareholders until 8 December 2023 (the
"Election Date").
Further details together with a copy of the Dividend Currency
Election Form, which should be sent to Link Group, 10(th) Floor,
Central Square, 29 Wellington Street, Leeds LS1 4DL when completed,
will be available on the Group's website shortly at
www.bpcruk.com/investor-materials . CREST shareholders must elect
via CREST.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt for the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DIVBPBMTMTBTTPJ
(END) Dow Jones Newswires
November 29, 2023 02:00 ET (07:00 GMT)
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
Von Dez 2023 bis Dez 2024